CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present on SY-1425, its oral first-in-class selective retinoic acid receptor alpha (RARα) agonist currently in a Phase 2 clinical trial in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), at the 14th International Symposium on Myelodysplastic Syndromes taking place from May 3-6 in Valencia, Spain. The presentation will be part of an industry-supported session focused on investigational therapies in development for MDS and other myeloid malignancies.
“We’re pleased to support the MDS Foundation in its efforts to bring together scientists, physicians and other healthcare providers to share the latest research in the diagnosis and treatment of MDS and to engage in the robust exchange of scientific information needed to accelerate the development of new therapies and improve the lives of MDS patients,” said David A. Roth, M.D., Chief Medical Officer of Syros.
Details on the presentation are as follows:
Date & Time: Thursday, May 4, from 1:15-2:45 p.m. CEST
Presentation
Title: SY-1425 (tamibarotene): a promising new approach for genomically
defined subsets of AML and MDS patients
Session Title:
Pipeline Research Session on MDS and Myeloid Malignancies
Presenter: David
A. Roth, M.D., Chief Medical Officer, Syros
Session Moderator:
Guillermo Sanz, M.D., Head of Clinical Hematology & Hematopoietic Cell
Transplantation Unit, Hospital Universitario y Politécnico La Fe
Location:
Palacio de Congresos de Valencia, Auditorium 2
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations. Because gene
expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is
advancing a growing pipeline of gene control medicines. Syros’ lead drug
candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical
trial for genomically defined subsets of patients with acute myeloid
leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7
inhibitor with potential in a range of solid tumors and blood cancers.
Led by a team with deep experience in drug discovery, development and
commercialization, Syros is located in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, including without
limitation statements regarding the clinical utility of Syros’ drug
candidates, including SY-1425, and the benefits of Syros’ gene control
platform. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’
‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’
‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various important
factors, including: Syros’ ability to: advance the development of its
programs, including SY-1425, under the timelines it projects in current
and future clinical trials; demonstrate in any current and future
clinical trials the requisite safety, efficacy and combinability of its
drug candidates; replicate scientific and non-clinical data in clinical
trials; successfully develop a companion diagnostic test to identify
patients with biomarkers associated with the RARA super-enhancer;
obtain and maintain patent protection for its drug candidates and the
freedom to operate under third party intellectual property; obtain and
maintain necessary regulatory approvals; identify, enter into and
maintain collaboration agreements with third parties; manage
competition; manage expenses; raise the substantial additional capital
needed to achieve its business objectives; attract and retain qualified
personnel; and successfully execute on its business strategies; risks
described under the caption “Risk Factors” in Syros’ Annual Report on
Form 10-K for the year ended December 31, 2016, which is on file with
the Securities and Exchange Commission; and risks described in other
filings that Syros makes with the Securities and Exchange Commission in
the future. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Syros expressly disclaims
any obligation to update any forward-looking statements, whether because
of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170501005358/en/
Media Contact:
Syros Pharmaceuticals
Naomi Aoki,
617-283-4298
naoki@syros.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Hannah
Deresiewicz, 212-362-1200
hannahd@sternir.com
Source: Syros Pharmaceuticals
Released May 1, 2017